Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib and Olaparib in Recurrent Ovarian, Fallopian Tube, Peritoneal, or Triple-Negative Breast Cancer
NCT01116648Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2010
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cediranib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), triple-negative breast cancer (TNBC), sponsored by National Cancer Institute. Started Apr 2010; status: active, not recruiting.
02
Drugs
cediranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01116648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01116648.